KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and Immunogenicity of an mRNA-1273 Booster in Children.

Vladimir Berthaud, C Buddy Creech, Christina A Rostad, Quito Carr, Liberation de Leon, Monika Dietrich, Anil Gupta, David Javita, Sharon Nachman, Swetha Pinninti, Mobeen Rathore, Carina A Rodriguez, Katherine Luzuriaga, William Towner, Anne Yeakey, Mollie Brown, Xiaoping Zhao, Weiping Deng, Wenqin Xu, Honghong Zhou, Bethany Girard, Roxanne Kelly, Karen Slobod, Evan J Anderson, Rituparna Das, Jacqueline Miller, Sabine Schnyder Ghamloush

Clin Infect Dis 79(6) 1524-1532

PMID39158584
PMCIDPMC11650855
DOI10.1093/cid/ciae420
发表日期2024-08-19
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25 µg) and 6-11 years (50 µg) had an acceptable safety profile and was immunogenic in the phase 2/3 KidCOVE study. We present data from KidCOVE participants who received an mRNA-1273 booster dose. METHODS: An mRNA-1273 booster dose (10 µg for children aged 6 months-5 years; 25 µg for children aged 6-11 years; age groups based on participant age at enrollment) was administered ≥6 months after primary series completion. The primary safety objective was the safety and reactogenicity of an mRNA-1273 booster dose. The primary immunogenicity objective was to infer efficacy of an mRNA-1273 booster dose by establishing noninferiority of neutralizing antibody (nAb) responses after a booster in children versus nAb responses observed after the mRNA-1273 primary series in young adults (18-25 years) from the pivotal efficacy study. Data were collected from March 2022 to June 2023. RESULTS: Overall, 153 (6 months-5 years) and 2519 (6-11 years) participants received an mRNA-1273 booster dose (median age at receipt of booster: 2 and 10 years, respectively). The booster dose safety profile was generally consistent with that of the primary series in children; no new safety concerns were identified. An mRNA-1273 booster dose elicited robust nAb responses against ancestral SARS-CoV-2 among children and met prespecified noninferiority success criteria versus responses observed after the primary series in young adults. CONCLUSIONS: Safety and immunogenicity data support administration of an mRNA-1273 booster dose in children aged 6 months to 11 years. CLINICAL TRIALS REGISTRATION: NCT04796896 (Clinicaltrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。